Navigation Links
arGEN-X Presents Significant Progress at BioPharm America 2011
Date:9/7/2011

ROTTERDAM, The Netherlands, September 7, 2011 /PRNewswire/ --

SIMPLE Antibody™ platform continues to demonstrate clear advantages in therapeutic antibody discovery


arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, will provide an update on this year's significant corporate progress  during a presentation by its CEO Tim Van Hauwermeiren at the BioPharm America conference in Boston, MA, USA (http://www.ebdgroup.com/bpa/).

In his presentation on Friday, September 9, Mr. Van Hauwermeiren will showcase the speed with which arGEN-X has developed its pipeline of novel therapeutic antibody candidates in cancer and inflammatory disease. In less than two years of operations, the Company has identified three completely novel lead antibodies of unprecedented specificity and potency and progressed them into preclinical studies. arGEN-X is also combining the power of its SIMPLE Antibody™ platform with POTELLIGENT® Technology licensed from BioWa, Inc., to increase the cytotoxic potency of its therapeutic leads even further.

The arGEN-X presentation will also announce the successful fulfilment of all milestones in its first biopharma collaboration, only five months from its initiation in January 2011. Upon completion of this program, arGEN-X delivered a panel of unique, diverse antibodies against a technically complex target provided by the partner. This success demonstrated how the SIMPLE Antibody™ platform could generate antibodies with outstanding qualities, even against targets beyond the reach of other antibody platforms.

Speaking further about the exciting developments at arGEN-X, Mr. Van Hauwermeiren said:

"The signficant progress we have made in 2011 is proof that our unique SIMPLE Antibody™ Platform is transforming the therapeutic antibody space. The speed and productivity of our first three internal programs have enabled us to begin discovery work on two new therapeutic targets. These developments have been instrumental in attracting companies seeking a reliable, robust platform for generation of therapeutic grade antibody candidates. Given this progress, I am excited about arGEN-X' prospects for the coming year."

Note for the editor

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company with a broadly applicable, proprietary SIMPLE Antibody™ platform. The platform allows arGEN-X to create an unparalleled diversity of in vivo generated antibody leads against a broad range of human disease targets. This superior choice of ultra-high affinity and highly potent leads, having best-in-class human homology, allows for more stringent lead selection criteria, thereby increasing the probability of success later in the drug development path. The Company has validated its platform on four human disease targets to date and has broad patent claims in place covering its technology.

arGEN-X' SIMPLE Antibody™ Platform is based on the active immunisation of Camelids with target antigens to deliver antibody variable regions that are perfectly matched to those of human antibodies. The combination of those variable domains with the constant domains of human antibodies, generates full size, human therapeutic antibodies.

The SIMPLE Antibody™ Platform enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

arGEN-X™ and SIMPLE Antibody™ are deposited trademarks of arGEN-X BV.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

For further information, please contact:


    
    Citigate Dewe Rogerson
    David Dible
    Mark Swallow
    Nina Enegren
    T: +44 207 282 2949/2948
    E: David.Dible@citigatedr.co.uk
    
    arGEN-X
    Tim Van Hauwermeiren, MSc, eMBA
    Chief Executive Officer
    T: +31 6 122 85 257
    E: tim.vh@arGEN-X.com



'/>"/>
SOURCE arGEN-X
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
2. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
3. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
4. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
5. Elan Pharmaceuticals Presents 7th Annual Danville Concours dElegance Weekend
6. Codexis Presents Carbon Capture Update at DoE/NETL Conference
7. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
8. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
9. Amerigroup Foundation Presents Grant to Rx Partnership
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Presents at 6th Annual Executive Forum on Pharmacy Benefit Management Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
Breaking Medicine News(10 mins):